Prime-boost vaccination using recombinant mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-I CRF01-AE gag in mice: Influence of immunization routes

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 40, Issue 2, 2009, Pages 273-281

  Promkhatkaew, Duanthanorm ^a,c   Matsuo, Kazuhiro ^b   Pinyosukhee, Nadthanan ^a   Thongdeejaroen, Wilai ^a   Leang Aramgul, Preecha ^a   Sawanpanyalert, Pathom ^a   Warachit, Paijit ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c Medical Biotechnology Center   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 63149161299     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bos JD, Kapsenberg ML. The skin immune system: progress in cutaneous biology. Immunol Today 1993; 14: 5-8.
2. + T cell responses to env. Vaccine 2000; 18: 123-33.
3. Gheradi MM, Ramirez JC, Estaban M. 11-12 enhancement of the cellular immune response against HIV-I env antigen in a DNA prime/ vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of 12-12 boost are mediated by nitric oxide. J Virol 2000; 74: 6278-86.
4. Gonzalo RM, Rodriguez D, Garcia-Sastre A, Rodriguez JR, Palese P, Estaban M. Enhanced CD8+ T cell responses to HIV-I env by combined immunization with influenza and vaccinia virus recombinant. Vaccine 1999; 17: 887-92.
5. Hanke T, Blanchard TJ. Schneider J, et al. Enhancement of MHC class I restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998; 16: 439-46.
6. Ishii K, Ueda Y, Matsuo K, et al. Structural analysis of vaccinia virus DIs strain: application as a new-replication deficient viral vector. Virology 2002; 320: 433-44.
7. Izumi Y, Ami Y, Matsuo K, et al. Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian-human immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys. J Virol 2003; 77:13248-56.
8. Kundig TM, Kalberger CP, Hengartner H, Zinkernagel RM. Vaccination with two different vaccinia recombinant viruses: longterm inhibition of secondary vaccination. Vaccine 1993; 11: 154-8.
9. Laemmli UK. Clevage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
10. Li S, Rodriguez M, Rodriguez D, et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell medicated protective immunity against malaria. Proc Natl Acad Sei USA 1993; 85: 105-9.
11. Miyahara Y, Garcia-Sastre A, Rodriguez D, et al,. Recombinant viruses expressing a human malaria antigen elicit a protective immune response in mice. Proc Natl Acad Sei USA 1998; 95: 3954-9.
12. Matsuo K, Nishino Y, Kimura T, et al. Highly conserved epitope domain in major core protein p24 is structurally similar among human, simian, and feline immunodeficiency viruses. / Gen Virol 1992; 73: 2445-50.
13. Morita M, Aoyama Y, Arita M, et al. Comparative studies of several vaccinia virus strain by intrathalamic inoculation into cynomolgus monkeys. Arch Viol 1977; 53: 97-208.
14. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sei USA 1996; 93: 11341-8.
15. Paoletti E. Applications of poxvirus vectors to vaccination: an update. Proc Natl Acad Sci USA 1996; 93:11349-53.
16. Promkhatkaew D, Pinyosukhee N, Thongdeejaroen W, Sutthent R, Sawanpanyalert P, Warachit P. Enhancement of cell-mediated immune response in mice by whole HIV-I gag in Mycobacterium bovis BCG as a live vaccine candidate. Southeast Asian }Trop Med Public Health 2009;40: 13-22.
17. Rayevskaya MV, Frankel FR. Systemic immunity and mucosal immunity are induced against HIV gag protein in mice by a new hyperattenuated strain Listeria monocytogenes. J Virol 2001; 75: 786-91.
18. Rodriguez D, Rodigurz J R, Rodriguez JF, Trauber D, Estaban M. Highly attenuated vaccinia virus mutants for the generation of safe re combinant virus. Proc Nalt Acad Sci USA 1989;86: 287-91.
19. Shen X, Justin Wong SB, Buck CB, Zhang J, Siliciano RF. Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J Immunol 2002; 169: 4222-9.
20. Tartaglia J, Excler JL, Rabib R, et al. Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retrov 1998; 14: S291-8.
21. nd Report. WHO Tech Rep Ser 1972; 493: 36.